In the original publication [1], there was a mistake in the Institutional Review Board Statement section of this article. The authors want to add the IRB number and Joint Biobank statement to the Institutional Review Board Statement section of this article. The authors state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated. The IRB approval number and Joint Biobank statement should be corrected as follows.
Institutional Review Board Statement: The study was approved by the Joint Institutional Review Board (JIRB) of the Taipei Medical University–Shuang Ho Hospital (Approval no.: N202101069, NBCT No.200039, NBCT No.220104, N202101065, N201801070, N202002052 and N202008022). Tissue samples from patients with primary and recurrent GBM were obtained from the Taipei Medical University—Joint Biobank, and complied with the recommendations of the Declaration of Helsinki for Biomedical Research.
Reference
- Su, I.-C.; Su, Y.-K.; Setiawan, S.A.; Yadav, V.K.; Fong, I.-H.; Yeh, C.-T.; Lin, C.-M.; Liu, H.-W. NADPH Oxidase Subunit CYBB Confers Chemotherapy and Ferroptosis Resistance in Mesenchymal Glioblastoma via Nrf2/SOD2 Modulation. Int. J. Mol. Sci. 2023, 24, 7706. [Google Scholar] [CrossRef] [PubMed]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).